Key result
Adropin reduces cardiomyocyte apoptosis and myocardial fibrosis in diabetic cardiomyopathy.
Why the study?
Myocardial apoptosis and fibrosis are hallmarks of diabetic cardiomyopathy, and although the peptide hormone adropin is linked to cardiovascular homeostasis and metabolic control, its function in diabetic cardiomyopathy remains unclear.
Does adropin attenuate myocardial fibrosis and inhibit cardiomyocyte apoptosis in a rat model of diabetic cardiomyopathy?
Does adropin attenuate myocardial fibrosis and inhibit cardiomyocyte apoptosis in a rat model of diabetic cardiomyopathy?
In a preclinical rat model of diabetic cardiomyopathy, adropin inhibited cardiomyocyte apoptosis and reduced myocardial fibrosis, suggesting potential as a therapeutic candidate for cardiac remodeling in diabetes.
Answers are grounded in this paper and cite their sources.
Should not change diabetic cardiomyopathy management; hypothesis-generating for adropin in cardiac remodeling.
Introduction: Myocardial apoptosis and fibrosis, which eventually result in heart failure, are the hallmarks of diabetic cardiomyopathy (DCM), a serious consequence of diabetes mellitus. A newly discovered peptide hormone called adropin has been linked to cardiovascular homeostasis and metabolic control. Its function in DCM is still not well known, though. The purpose of this study is to examine how Adropin affects myocardium fibrosis and apoptosis in a rat model of DCM. Methods: Eight-week-old male Wistar rats were randomly assigned to four groups: normal control (CON), DCM model (DCM), adropin-treated (ADR), and perindopril-treated (PER). Streptozotocin was used to induce DCM. The rats were put to death after four weeks, and their hearts were removed. Masson's trichrome staining was used to measure myocardial fibrosis, while TUNEL staining was used to identify cardiomyocyte apoptosis. Western blot analysis was used to determine the expression levels of proteins linked to apoptosis. Results: The DCM group showed more severe myocardial fibrosis and a significantly higher rate of cardiomyocyte apoptosis when compared to the CON group. All differences reached statistical significance (P < 0.05). In particular, Bax and cleaved caspase-3 expression levels were significantly higher (P < 0.05) while Bcl-2 protein expression was significantly lower (P < 0.05). On the other hand, there were statistically significant differences between the ADR and PER groups and the DCM group in terms of cardiomyocyte apoptosis and myocardial fibrosis. Additionally, Bax and cleaved caspase-3 expression levels were significantly lower (P < 0.05), whereas Bcl-2 expression was significantly higher (P = 0.001) and (P = 0.002).Conclusion: In rats with diabetic cardiomyopathy, adropin can prevent cardiomyocyte death and enhance cardiac remodeling, indicating its potential as a therapeutic drug.
No takes yet. Share an insight, caveat, or question.
Zhuang et al. (2026) studied Diabetic cardiomyopathy (DCM) in rats. Adropin vs. Normal control (CON), untreated DCM model (DCM), and perindopril-treated (PER) groups was evaluated on Myocardial fibrosis and cardiomyocyte apoptosis (p=<0.05). Adropin reduced cardiomyocyte apoptosis and myocardial fibrosis compared to untreated DCM rats, lowering Bax/cleaved caspase-3 and increasing Bcl-2.
Synapse has enriched 10 related papers. Consider them for comparative context: